{"id":"https://openalex.org/W2767436767","doi":"https://doi.org/10.1200/jco.2017.35.15_suppl.4074","title":"Safety and activity of the pan-fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients (Pts) with molecularly selected advanced cholangiocarcinoma (CCA).","display_name":"Safety and activity of the pan-fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients (Pts) with molecularly selected advanced cholangiocarcinoma (CCA).","publication_year":2017,"publication_date":"2017-05-20","ids":{"openalex":"https://openalex.org/W2767436767","doi":"https://doi.org/10.1200/jco.2017.35.15_suppl.4074","mag":"2767436767"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2017.35.15_suppl.4074","doi":"https://doi.org/10.1200/jco.2017.35.15_suppl.4074","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2017.35.15_suppl.4074","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5021624793","display_name":"Jean\u2010Charles Soria","orcid":"https://orcid.org/0000-0001-9597-0701","observed_orcids":["https://orcid.org/0000-0001-9597-0701"]},"institutions":[{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]},{"id":"https://openalex.org/I4405269973","display_name":"Fondation Gustave Roussy","ror":"https://ror.org/05rfnt234","country_code":"FR","type":"nonprofit","lineage":["https://openalex.org/I4405269973"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Jean-Charles Soria","raw_affiliation_strings":["Drug Development Department (DITEP), Gustave Roussy, Villejuif, France;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Drug Development Department (DITEP), Gustave Roussy, Villejuif, France;","institution_ids":["https://openalex.org/I2801843802","https://openalex.org/I4405269973"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005968330","display_name":"John H. Strickler","orcid":"https://orcid.org/0000-0001-7579-1175","observed_orcids":["https://orcid.org/0000-0001-7579-1175"]},"institutions":[{"id":"https://openalex.org/I4210126298","display_name":"Duke Medical Center","ror":"https://ror.org/03njmea73","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876"]},{"id":"https://openalex.org/I4390039326","display_name":"Duke Cancer Institute","ror":"https://ror.org/04vt65461","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210126298","https://openalex.org/I4210144876","https://openalex.org/I4390039326"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"John H. Strickler","raw_affiliation_strings":["Duke Cancer Institute, Duke University Medical Center, Durham, NC;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Duke Cancer Institute, Duke University Medical Center, Durham, NC;","institution_ids":["https://openalex.org/I4210126298","https://openalex.org/I4390039326"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068824818","display_name":"Ramaswamy Govindan","orcid":"https://orcid.org/0000-0002-6964-9612","observed_orcids":["https://orcid.org/0000-0002-6964-9612"]},"institutions":[{"id":"https://openalex.org/I204465549","display_name":"Washington University in St. Louis","ror":"https://ror.org/01yc7t268","country_code":"US","type":"education","lineage":["https://openalex.org/I204465549"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ramaswamy Govindan","raw_affiliation_strings":["Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO;","institution_ids":["https://openalex.org/I204465549"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083417260","display_name":"Seungjean Chai","orcid":"https://orcid.org/0000-0003-1324-3362","observed_orcids":["https://orcid.org/0000-0003-1324-3362"]},"institutions":[{"id":"https://openalex.org/I4210100342","display_name":"Levine Cancer Institute","ror":"https://ror.org/0174nh398","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1334069289","https://openalex.org/I4210100342"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Seungjean Chai","raw_affiliation_strings":["Levine Cancer Institute, Charlotte, NC;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Levine Cancer Institute, Charlotte, NC;","institution_ids":["https://openalex.org/I4210100342"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081735541","display_name":"Nancy Chan","orcid":"https://orcid.org/0000-0002-0047-5108","observed_orcids":["https://orcid.org/0000-0002-0047-5108"]},"institutions":[{"id":"https://openalex.org/I4390039325","display_name":"Rutgers Cancer Institute","ror":"https://ror.org/0060x3y55","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I102322142","https://openalex.org/I4390039302","https://openalex.org/I4390039325"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Nancy Chan","raw_affiliation_strings":["Rutgers Cancer Institute of New Jersey, New Brunswick, NJ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Rutgers Cancer Institute of New Jersey, New Brunswick, NJ;","institution_ids":["https://openalex.org/I4390039325"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088121773","display_name":"Vanesa Quiroga","orcid":"https://orcid.org/0000-0002-7852-474X","observed_orcids":["https://orcid.org/0000-0002-7852-474X"]},"institutions":[{"id":"https://openalex.org/I4210107147","display_name":"Institut Catal\u00e0 d'Oncologia","ror":"https://ror.org/01j1eb875","country_code":"ES","type":"government","lineage":["https://openalex.org/I4210107147"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Vanesa Quiroga-Garcia","raw_affiliation_strings":["Institut Catal\u00e0 d'Oncologia, Hospital Germans Trias i Pujol, Badalona, Spain;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Institut Catal\u00e0 d'Oncologia, Hospital Germans Trias i Pujol, Badalona, Spain;","institution_ids":["https://openalex.org/I4210107147"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045670207","display_name":"Rastislav Bahleda","orcid":"https://orcid.org/0009-0001-8245-0544","observed_orcids":["https://orcid.org/0009-0001-8245-0544"]},"institutions":[{"id":"https://openalex.org/I2801843802","display_name":"Institut Gustave Roussy","ror":"https://ror.org/0321g0743","country_code":"FR","type":"facility","lineage":["https://openalex.org/I2801843802"]}],"countries":["FR"],"is_corresponding":false,"raw_author_name":"Rastislav Bahleda","raw_affiliation_strings":["Gustave Roussy Cancer Campus and University Paris-Sud, Villejuif, France;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Gustave Roussy Cancer Campus and University Paris-Sud, Villejuif, France;","institution_ids":["https://openalex.org/I2801843802"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112673302","display_name":"Cinta Hierro","orcid":"https://orcid.org/0000-0002-0435-2172","observed_orcids":["https://orcid.org/0000-0002-0435-2172"]},"institutions":[{"id":"https://openalex.org/I4210127641","display_name":"Vall d'Hebron Hospital Universitari","ror":"https://ror.org/03ba28x55","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I157913058","https://openalex.org/I4210127641","https://openalex.org/I4210153292"]},{"id":"https://openalex.org/I4387155398","display_name":"Vall d'Hebron Institute of Oncology","ror":"https://ror.org/054xx3904","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4387153040","https://openalex.org/I4387155398"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Cinta Hierro","raw_affiliation_strings":["Medical Oncology Department, Vall d'Hebron University Hospital, Molecular Therapeutics Research Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Medical Oncology Department, Vall d'Hebron University Hospital, Molecular Therapeutics Research Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain;","institution_ids":["https://openalex.org/I4210127641","https://openalex.org/I4387155398"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109119754","display_name":"Bob Zhong","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bob Zhong","raw_affiliation_strings":["Janssen Research and Development, LLC, Raritan, NJ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Research and Development, LLC, Raritan, NJ;","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024388671","display_name":"Martha Gonzalez","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Martha Gonzalez","raw_affiliation_strings":["Janssen Research and Development, LLC, Raritan, NJ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Research and Development, LLC, Raritan, NJ;","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006620245","display_name":"Ademi Santiago-Walker","orcid":"https://orcid.org/0000-0002-3139-1556","observed_orcids":["https://orcid.org/0000-0002-3139-1556"]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ademi E. Santiago-Walker","raw_affiliation_strings":["Janssen Research and Development, LLC, Raritan, NJ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Research and Development, LLC, Raritan, NJ;","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108888488","display_name":"Trilok V. Parekh","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Trilok V. Parekh","raw_affiliation_strings":["Janssen Research and Development, LLC, Raritan, NJ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Research and Development, LLC, Raritan, NJ;","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102007098","display_name":"Feng Roger Luo","orcid":"https://orcid.org/0000-0001-6272-5005","observed_orcids":["https://orcid.org/0000-0001-6272-5005"]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Feng Roger Luo","raw_affiliation_strings":["Janssen Research and Development, LLC, Raritan, NJ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Research and Development, LLC, Raritan, NJ;","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5048842913","display_name":"Loretta Sullivan-Chang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Loretta Sullivan-Chang","raw_affiliation_strings":["Janssen Research and Development, LLC, Raritan, NJ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Research and Development, LLC, Raritan, NJ;","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100405584","display_name":"Hong Xie","orcid":"https://orcid.org/0000-0001-9715-955X","observed_orcids":["https://orcid.org/0000-0001-9715-955X"]},"institutions":[{"id":"https://openalex.org/I4405282460","display_name":"Janssen Research & Development (United States)","ror":"https://ror.org/05wae1a98","country_code":"US","type":"company","lineage":["https://openalex.org/I1330063522","https://openalex.org/I4405282460"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hong Xie","raw_affiliation_strings":["Janssen Research and Development, LLC, Raritan, NJ;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Janssen Research and Development, LLC, Raritan, NJ;","institution_ids":["https://openalex.org/I4405282460"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5015190461","display_name":"Josep M. Tabernero","orcid":"https://orcid.org/0000-0002-2495-8139","observed_orcids":["https://orcid.org/0000-0002-2495-8139"]},"institutions":[{"id":"https://openalex.org/I4387155398","display_name":"Vall d'Hebron Institute of Oncology","ror":"https://ror.org/054xx3904","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I4387153040","https://openalex.org/I4387155398"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Josep Tabernero","raw_affiliation_strings":["Vall d\u2019Hebron University Hospital Institute of Oncology (VHIO), Barcelona, Spain;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vall d\u2019Hebron University Hospital Institute of Oncology (VHIO), Barcelona, Spain;","institution_ids":["https://openalex.org/I4387155398"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":11,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":24,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"35","issue":"15_suppl","first_page":"4074","last_page":"4074"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11364","display_name":"Cholangiocarcinoma and Gallbladder Cancer Studies","score":0.9775000214576721,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11364","display_name":"Cholangiocarcinoma and Gallbladder Cancer Studies","score":0.9775000214576721,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12287","display_name":"Fibroblast Growth Factor Research","score":0.015399999916553497,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11067","display_name":"Colorectal Cancer Treatments and Studies","score":0.0010999999940395355,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/erdafitinib","display_name":"erdafitinib","score":0.9990000128746033},{"id":"https://openalex.org/keywords/fgfr-inhibitors","display_name":"FGFR inhibitors","score":0.753000020980835},{"id":"https://openalex.org/keywords/cholangiocarcinoma","display_name":"cholangiocarcinoma","score":0.9570000171661377},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.8619999885559082},{"id":"https://openalex.org/keywords/stomatitis","display_name":"stomatitis","score":0.6019999980926514},{"id":"https://openalex.org/keywords/hyperphosphatemia","display_name":"hyperphosphatemia","score":0.8849999904632568},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.7739999890327454},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7049999833106995},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.6019999980926514},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.5590000152587891},{"id":"https://openalex.org/keywords/intermittent-dosing","display_name":"intermittent dosing","score":0.5960000157356262},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.6909999847412109},{"id":"https://openalex.org/keywords/safety-and-tolerability","display_name":"safety and tolerability","score":0.5960000157356262}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9157269597053528},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6376433372497559},{"id":"https://openalex.org/C82867764","wikidata":"https://www.wikidata.org/wiki/Q24780051","display_name":"Fibroblast growth factor receptor","level":4,"score":0.5999956727027893},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5949040651321411},{"id":"https://openalex.org/C2777054765","wikidata":"https://www.wikidata.org/wiki/Q6402731","display_name":"Dysgeusia","level":3,"score":0.5405169725418091},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.49569952487945557},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.42318516969680786},{"id":"https://openalex.org/C2779051857","wikidata":"https://www.wikidata.org/wiki/Q911386","display_name":"Stomatitis","level":2,"score":0.4211497902870178},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.32131898403167725},{"id":"https://openalex.org/C74373430","wikidata":"https://www.wikidata.org/wiki/Q24727126","display_name":"Fibroblast growth factor","level":3,"score":0.1696470081806183},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.138469398021698}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2017.35.15_suppl.4074","doi":"https://doi.org/10.1200/jco.2017.35.15_suppl.4074","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2017.35.15_suppl.4074","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2947335179","https://openalex.org/W2897763490","https://openalex.org/W7117456398","https://openalex.org/W4317863092","https://openalex.org/W4206736819","https://openalex.org/W2946128073","https://openalex.org/W4399881091","https://openalex.org/W4401528511","https://openalex.org/W4387810549","https://openalex.org/W2760207881"],"abstract_inverted_index":{"4074":[0],"Background:":[1],"Erdafitinib":[2,328],"(JNJ-42756493)":[3],"is":[4],"a":[5,65,104,300],"potent,":[6],"oral":[7],"pan-FGFR":[8],"tyrosine":[9],"kinase":[10],"inhibitor":[11],"that":[12],"demonstrated":[13],"encouraging":[14,330],"preliminary":[15],"clinical":[16,331],"activity":[17,332],"and":[18,95,109,125,191,218,290,333,341],"manageable":[19],"adverse":[20],"events":[21],"(AEs)":[22],"in":[23,29,89,193,232,336],"its":[24],"first-in-human":[25],"phase":[26,116],"1":[27,234],"study":[28,48,325],"advanced":[30,57,339],"solid":[31,58],"tumors":[32],"(NCT01703481).":[33],"Here":[34],"we":[35],"report":[36],"results":[37,345],"from":[38,42],"pts":[39,50,69,132,160,166,195,322,337],"with":[40,56,68,133,180,338],"CCA":[41,135,194,340],"this":[43],"study.":[44,348],"Methods:":[45],"This":[46],"4-part":[47],"enrolled":[49],"age":[51,153],"\u2265":[52],"18":[53],"years":[54],"(y)":[55],"tumors.":[59],"Dose":[60],"escalation":[61],"(part":[62],"1)":[63,144],"followed":[64],"3+3":[66],"design,":[67],"receiving":[70],"ascending":[71],"doses":[72,118],"of":[73,119,158,165,294,303,317],"erdafitinib":[74,181,187],"continuously":[75],"or":[76,97,145],"intermittently":[77],"(7":[78],"days":[79,81],"on/7":[80],"off).":[82],"Subsequent":[83],"parts":[84],"required":[85],"FGFR":[86,342],"gene":[87],"alterations":[88],"the":[90,285,291,318],"tumor,":[91],"including":[92],"activating":[93],"mutations":[94],"translocations":[96],"other":[98,199],"FGFR-activating":[99],"aberrations.":[100],"Part":[101],"2":[102,117,321],"was":[103,154,182,196,256,278,296,309],"pharmacodynamics":[105],"cohort.":[106],"Parts":[107],"3":[108,238,281],"4":[110],"were":[111,136,161,205,230,283],"dose-expansion":[112],"cohorts":[113],"for":[114],"recommended":[115],"9":[120,139],"mg":[121,127,140,147,287],"once":[122],"daily":[123],"(QD)":[124],"10":[126,146,286],"intermittently,":[128],"respectively.":[129],"Results:":[130],"Eleven":[131],"FGFR-aberrant":[134],"treated":[137],"at":[138,284],"QD":[141],"(n":[142,149,240],"=":[143,150,241],"intermittent":[148,288],"10).":[151],"Median":[152,177],"60":[155],"y;":[156],"7":[157],"11":[159],"female":[162],"(64%).":[163],"73%":[164],"had":[167,173,267],"ECOG":[168],"performance":[169],"status":[170],"1.":[171],"All":[172,280],"prior":[174],"systemic":[175],"therapy.":[176],"treatment":[178],"duration":[179,293],"5.3":[183],"months":[184],"(mo).":[185],"Systemic":[186],"exposure,":[188],"per":[189,253],"Cmax":[190],"AUC,":[192],"similar":[197],"to":[198],"indications.":[200],"The":[201,244],"most":[202],"common":[203],"AEs":[204,229],"stomatitis":[206,239],"(82%),":[207],"hyperphosphatemia":[208],"(64%),":[209],"dry":[210,215],"mouth":[211],"(55%),":[212],"dysgeusia":[213],"(45%),":[214,217,220],"skin":[216],"asthenia":[219],"mostly":[221],"grade":[222,227,237],"1/2":[223],"severity.":[224],"No":[225],"drug-related":[226],"\u22653":[228],"reported":[231],">":[233],"pt":[235],"except":[236],"2;":[242],"18%).":[243],"objective":[245],"response":[246,295],"rate,":[247],"all":[248],"confirmed":[249],"partial":[250],"responses":[251],"(PRs)":[252],"RECIST":[254],"1.1,":[255],"27.3%":[257,265],"(3/11;":[258],"95%":[259],"CI":[260,313],"6,":[261],"61);":[262],"an":[263],"additional":[264],"(3/11)":[266],"stable":[268],"disease":[269,275],"as":[270],"their":[271],"best":[272],"response.":[273],"Overall":[274],"control":[276],"rate":[277],"55%.":[279],"PRs":[282],"dosage,":[289],"median":[292,301,306],"12.9":[297],"mo.":[298],"With":[299],"follow-up":[302],"5.1":[304,310],"mo,":[305],"progression-free":[307],"survival":[308],"mo":[311],"(95%":[312],"1.6,":[314],"16.4).":[315],"As":[316],"cutoff":[319],"date,":[320],"continue":[323],"on":[324],"treatment.":[326],"Conclusions:":[327],"showed":[329],"minimal":[334],"toxicity":[335],"alterations.":[343],"These":[344],"warrant":[346],"further":[347],"Clinical":[349],"trial":[350],"information:":[351],"NCT01703481.":[352]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":7},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":2},{"year":2017,"cited_by_count":1}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2017-11-17T00:00:00"}